Helsinn Healthcare

• NCT06065722

  Collaborator, Phase 2, Status unknown, 100 people, 4 Oct 2023

• NCT04817189

  Phase 4, Completed, 414 people, 26 Mar 2021

• NCT03773302

  Collaborator, Phase 3, Terminated, 48 people, 12 Dec 2018

• NCT03668639

  Collaborator, Phase 2/3, Status unknown, 80 people, 12 Sept 2018

• NCT03403712

  Phase 3, Completed, 404 people, 19 Jan 2018

• NCT02557035

  Phase 3, Completed, 441 people, 22 Sept 2015

• NCT02517021

  Phase 3, Completed, 405 people, 6 Aug 2015

• NCT02267278

  Collaborator, Phase 2, Completed, 25 people, 17 Oct 2014

• NCT01993641

  Phase 2, Completed, 45 people, 25 Nov 2013

• NCT01376297

  Phase 3, Completed, 413 people, 20 Jun 2011

• NCT01363479

  Phase 3, Completed, 743 people, 1 Jun 2011

• NCT01339260

  Phase 3, Completed, 1,455 people, 20 Apr 2011

• NCT01074697

  Collaborator, Phase 3, Completed, 246 people, 24 Feb 2010

• NCT00090025

  Phase 3, Terminated, 248 people, 23 Aug 2004

• Efficacy and safety of semaglutide for obesity and hyperphagia in adults with Prader-Willi syndrome

  Consulting or advice, 3 Sept 2026

Sources: pubmed.ncbi.nlm.nih.gov